Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

• Published in: Cancer investigation Vol. 28; no. 4; pp. 393 - 398
• Main Authors: Pau, Enrique Carrillo-de Santa, Arias, Fernando Carrillo, Pelaez, Enrique Caso, Trueba, Ignacio Muguruza, Hernández, Ignacio Sánchez, Molina, Gemma María Muñoz, Balsalobre, Ramón Moreno, López, Silvia Sacristán, Gómez-Pinillos, Alejandro, Toledo Lobo, Maria del Val
• Format: Journal Article
• Language: English
• Published: 01-05-2010
• ISSN: 0735-7907; 1532-4192
• DOI: 10.3109/07357900903405900

AIMEvaluate the serum vascular endothelial growth factor (VEGF) levels in the prognosis of lung cancer patients.METHODSFifty-four serum samples were analyzed for VEGF concentrations (79.3% nonsmall cell lung cancer (NSCLC) and 20.7% small cell lung cancer).RESULTSPatients with serum VEGF-A levels higher than the mean of the patients studied (434.93 pg/mL) presented a shorter median survival time than those with lower levels (p =.04), as in patients with NSCLC tumors (p =.04) and in those with stages I-II (p <.05), and high serum VEGF-A levels.CONCLUSIONElevated VEGF serum levels have a negative prognostic impact on survival in NSCLC and early stages of lung cancer patients.